Publications by authors named "M Natalia Calienni"

The aims of this work were to formulate cannabidiol in different lipid carriers for skin delivery after topical application and to study their stability, interaction with the skin, and antibacterial activity. Solid lipid nanoparticles and nanostructured lipid carriers loaded with cannabidiol were prepared and characterized in terms of their physicochemical properties, colloidal stability, protection of the antioxidant capacity of cannabidiol, as well as their retention over time. Skin penetration was assessed using an in vitro model with human skin.

View Article and Find Full Text PDF

Cellular motility is essential for making and maintaining multicellular organisms throughout their lifespan. Migrating cells can move either individually or collectively by a crawling movement that links the cytoskeletal activity to the adhesion surface. In vitro stimulation by electric fields can be achieved by direct, capacitive or inductive coupled setups.

View Article and Find Full Text PDF

The rheological and viscoelastic properties of hybrid formulations composed of vehicles designed for cutaneous topical application and loaded with ultradeformable liposomes (UDL) were assessed. UDL were selected for their established ability to transport both lipophilic and hydrophilic compounds through the skin, and are applicable in pharmaceuticals and cosmetics. Formulations underwent flow analysis and were fitted to the Herschel-Bulkley model due to their prevalent non-Newtonian behavior in most cases.

View Article and Find Full Text PDF

In-vitro viral studies are still fundamental for biomedical research since studying the virus kinetics on cells is crucial for the determination of the biological properties of viruses and for screening the inhibitors of infections. Moreover, testing potential viral contaminants is often mandatory for safety evaluation. Nowadays, viral cytopathic effects are mainly evaluated through end-point assays requiring dye-staining combined with optical evaluation.

View Article and Find Full Text PDF

Vismodegib is a first-in-class inhibitor for advanced basal cell carcinoma treatment. Its daily oral doses present a high distribution volume and several side effects. We evaluated its skin penetration loaded in diverse nanosystems as potential strategies to reduce side effects and drug quantities.

View Article and Find Full Text PDF